All In Biotech

Drug Trial Radar · NCT02089087

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients

A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CFZ533 in Healthy Subjects and Rheumatoid Arthritis Patients

Last checked: Nov 19, 2026Latest source record: Dec 11, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

75

Actual

Start

Jan 7, 2013

Primary completion

Feb 3, 2017

Study completion Feb 3, 2017

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 17, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single intravenous and subcutaneous doses of CFZ533 in healthy subjects and intravenous doses in rheumatoid arthritis patients.

Conditions

  • Rheumatoid Arthritis

Interventions

  • CFZ533Biological

    Single dose at varying dosage levels depending on treatment assignment

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with adverse events as a measure of safety and tolerabilityTime frame: 7 months

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Anniston, Alabama

  • Novartis Investigative Site

    Miami, Florida

  • Novartis Investigative Site

    South Miami, Florida

  • Novartis Investigative Site

    Lincoln, Nebraska

  • Novartis Investigative Site

    Duncansville, Pennsylvania

  • Novartis Investigative Site

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.